HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

NeurologyLive® Friday 5 — September 2, 2022

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 2, 2022.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Cognition and Brain Health Biomarkers in Multiple Sclerosis

In episode 7 of the NeurologyLive® Ever Changing Face of MS series, "Cognition & Brain Health in Multiple Sclerosis," Randall Schapiro, MD, FAAN, and Jeffrey Wilken, PhD, explore the idea of cognition and brain health biomarkers in multiple sclerosis and provide imaging and diagnostic recommendations.

2: Overview of the Prevalence and Variety of Pediatric Sleep Disorders: Carol Rosen, MD

The professor of pediatrics at Case Western University provided insight on the typical sleep issues seen in children and adolescents, and how they impact overall quality of life.

3: NeuroVoices: Paul Lipkin, MD, on Improved CDC Guidelines for Developmental Milestones

In the latest edition of our in-depth Q&A series, the director of medical outpatient services at the Kennedy Krieger Institute discussed the changes and implications of new CDC guidelines on developmental milestones for growing children.

4: Institutional Perspectives in Neurology, Chaired by Augusto Miravalle, MD

Chaired by Augusto Miravalle, MD, of the University of Colorado, the presentations also feature Barry Hendin, MD, of the Center for Neurology and Spine; Ilana B. Katz Sand, MD, of Mount Sinai; Brett Fling, PhD, of Colorado State University; and Gavin Giovannoni, MBBCh, PhD, of Queen Mary University of London.

5: Role of the Cognitive Stress Test in Improving Future Alzheimer Clinical Trials: Rosie Curiel, PsyD

The associate professor of neuropsychology at the University of Miami Miller School of Medicine discussed how a new innovative tool can further characterize cognitive status and improve the evaluation of agents in development for Alzheimer disease.